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1 |  INTRODUCTION
A 31‐year‐old woman presented to the Emergency 
Department with a painful, cold, blue left leg with absent dis-
tal pulses. Four days previously, she had been diagnosed with 
a deep vein thrombosis (DVT) by Doppler ultrasound after 
presenting with left leg swelling and had been commenced 
simultaneously on low‐molecular‐weight heparin (LMWH, 
Dalteparin 200 U/kg) and warfarin loading (10, 5, and 5 mg). 
Aside from a 3‐month history of recurrent thrombophlebitis, 
she was formerly fit and well with no significant past medical 
or family history and had never smoked. She had had two 
successful pregnancies and one miscarriage 10 years previ-
ously. Her INR was 5.78 with a platelet count of 205.
A CT angiogram confirmed an extensive left leg DVT 
and secondary arterial compromise leading to venous gan-
grene (Figure 1). There was preserved flow in the popli-
teal artery, but no detectable arterial flow in the foot, and 
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We report a case of lung adenocarcinoma‐associated hypercoagulability leading to 
venous limb gangrene, managed successfully with argatroban and then dabigatran. 
Use of idarucizumab permitted diagnostic investigations, leading to targeted antineo-
plastic therapy with crizotinib, surgical resection with curative intent, and continued 
survival over 2 years after the index event.
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there were thromboses in posterior tibial and popliteal veins. 
Although directed thrombolysis with alteplase and hepa-
rin provided some benefit, the limb was not viable and the 
patient underwent an above knee amputation the following 
day. A heparin infusion was commenced and maintained to 
an aPTT of 45‐60 seconds for 72 hours while gradual recov-
ery from the high INR was awaited. LMWH and warfarin 
were recommenced 96 hours after presentation when the pa-
tient's INR was <2.0. Thrombocytosis ensued (to a peak of 
710 × 10*9/L), and the INR rose to 5.4 in the next 72 hours.
She was investigated for an underlying malignancy (breast 
exam, abdominal ultrasound, and tumor markers). A throm-
bophilia screen identified a heterozygous factor V Leiden 
mutation and positive anticardiolipin antibodies (ACA IgG 
48 GPLU/mL, >99th centile). Low levels of Proteins C and 
S were assumed to be due to warfarin therapy. An Acustar® 
chemoluminescence assay for HIT antibodies was negative.
The patient was diagnosed with further DVTs in her right 
arm and right internal jugular vein, and a CT pulmonary an-
giogram, performed due to persistent tachycardia, revealed 
pulmonary emboli. The patient was switched to fondaparinux 
7.5 mg and underwent plasmapheresis for a potential diag-
nosis of catastrophic antiphospholipid antibody syndrome 
(CAPS). The final report of her CT pulmonary angiogram 
identified an 11 mm left lower lobe lung lesion with medias-
tinal and hilar lymphadenopathy (Figure 2).
Despite a therapeutic anti‐Xa level on fondaparinux 
(1.03 IU/mL, measured 4‐5 hours postinjection), the patient 
developed a further thrombosis in her right common femoral 
vein. A decision was made to switch her onto an argatroban 
infusion. Argatroban is a direct thrombin inhibitor, licensed 
for HIT, with a half‐life of 45 minutes and monitored by 
the aPTT, with no specific reversal agent. Despite being ir-
reversible, the short half‐life allowed CT‐guided needle bi-
opsy of the previously identified left lower lobe lung lesion. 
Argatroban was discontinued 6 hours preprocedure and re-
started 8 hours postprocedure. While there was no bleeding 
complication, the patient developed a symptomatic left su-
perior caval vein thrombosis, associated with a peripherally 
inserted central catheter. Histopathological analysis of the 
lesion showed a moderate to poorly differentiated adenocar-
cinoma with strong diffuse staining for thyroid transcription 
factor 1 (TTF1) and cytokeratin 7 (CK7), consistent with an 
adenocarcinoma of lung origin.
Staging with PET‐CT (Figure 3) showed 18FDG uptake 
in the left lower lobe lesion as well as in mediastinal and 
F I G U R E  1  Angiogram showing reduced flow in the left 
common femoral vein due to thrombus (indicated)
F I G U R E  2  CT scan of chest identifying a pulmonary lesion 
(red) and an infarct (blue) due to a pulmonary embolus
F I G U R E  3  A PET‐CT scan showing FDG‐uptake into the 
pulmonary lesion (arrow), with associated lymphadenopathy
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ipsilateral hilar lymph nodes (stations 4L, 6, 7, 10L, and 
11L). If this nodal 18FDG‐avidity was confirmed as due to 
spread of cancer, this would have precluded radical surgi-
cal treatment. Therefore, the argatroban infusion was again 
interrupted to allow for endobronchial ultrasound‐guided 
transbronchial needle aspiration (EBUS‐TBNA) of the sta-
tion 4L and seven nodes. These biopsies confirmed T1a N2 
M0 adenocarcinoma of lung origin (TTF1 positive with an 
ALK translocation).
The patient was converted to dabigatran 150 mg BD, as 
it was felt to resemble most closely the action of argatro-
ban, although the failure of LMWH anticoagulation may 
have been related to the warfarin‐induced drop in Protein 
C. Oncological review determined that the patient should 
receive chemotherapy with crizotinib (a tyrosine kinase in-
hibitor), due to the presence of an EML4‐ALK translocation 
of the adenocarcinoma, despite her WHO performance status 
of three (attributable to the recent amputation and ongoing 
inpatient stay). There was concern regarding a potential in-
teraction between crizotinib and dabigatran as the former has 
been shown to act as an inhibitor of P‐glycoprotein and the 
latter is a P‐glycoprotein substrate.1,2 The theoretical risk of 
increased dabigatran levels was not observed: levels were 
measured by calibrated diluted thrombin assay (Hyphen®) on 
multiple occasions 90 minutes postadministration of dabiga-
tran, but no detectable dabigatran was demonstrated. There 
were no clinical concerns over the subsequent 9 months of 
combination therapy.
Repeat imaging after her second cycle of crizotinib 
showed significant response in terms of tumor size, as well 
as resolution of her thromboses. After six cycles of crizo-
tinib, PET‐CT indicated an excellent metabolic response with 
a reduction in the primary lesion's size to 8 × 6 mm (with 
no significant tracer uptake) and resolution of the medias-
tinal and hilar lymph node enlargement. After seven cycles, 
EUS‐TBNA/EUS(B)‐FNA showed that the only lymph node 
amenable to biopsy was at mediastinal station 7 (subcarinal), 
which contained no malignancy. After eight cycles, medi-
astinoscopy was also negative for malignancy and so, after 
nine cycles, she proceeded to a uniportal VATS left lower 
lobectomy and lymphadenectomy. The decision to proceed 
to surgery was in view of the clinical complete response 
to crizotinib and drug‐related toxicity of CTCAE grade 2 
dysgeusia.
Dabigatran was successfully bridged with idarucizumab 
with no concern of external bleeding for her restaging bi-
opsies, with treatment restarted 8 hours postprocedure at 
150 mg. For the lobectomy, the patient was again bridged 
with idarucizumab, but postoperatively treated with argatro-
ban for 24 hours prior to recommencing dabigatran.
Postoperative pathology revealed areas of fibrosis but no 
active tumor in the lung and isolated single cell deposits in 
station 5 lymph nodes [Figure 4], staged as ypT0 ypN0 (i+). 
It was not possible to test these cells for ALK translocation 
by IHC or FISH. A shared decision was made to commence 
standard adjuvant chemotherapy, and vinorelbine/cisplatin 
was commenced for two cycles, followed by a change to 
vinorelbine/carboplatin for the final two cycles due to drug 
toxicity.
At the time of writing, the patient remains under long‐term 
thoracic oncology follow‐up with her most recent imaging, 
over 2 years after initial presentation, showing no evidence 
of cancer recurrence.
2 |  DISCUSSION
An unprovoked DVT in a young person should always raise 
the possibility of a thrombophilia or an undiagnosed cancer. 
Outpatient management of DVT is now the standard of care, 
and investigations for any underlying cause are fast‐tracked 
rather than performed on initial presentation. Warfarin and 
LMWH have an exceedingly low rate of failure,3 and rep-
resentation within 96 hours of commencing anticoagulation 
is likely due to one of four differential diagnoses: cancer, 
antiphospholipid syndrome, heparin‐induced thrombocy-
topenia (HIT), or noncompliance. The 3‐month history of 
recurrent thrombophlebitis could also suggest Trousseau's 
syndrome (recurrent thrombophlebitis arising from the for-
mation of small blood clots in association with malignancy). 
Her INR was raised, suggesting that she was not overtly 
hypercoagulable. The presentation with an acutely painful 
F I G U R E  4  Postoperative histology 
from station five lymph nodes, using brown 
immunohistochemistry showing isolated 
tumor cells. A, Thyroid transcription factor 
1 (TTF1) nuclear staining. B, Cytokeratin 
(MNF116) cytoplasmic staining
(A) (B)
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limb with preserved pulses could also alert the clinician 
to phlegmasia coerulea dolens: the classic presentation is 
with detectable pulses; however, venous and microvascular 
thrombosis will eventually reduce the runoff from the small 
distal arteries.
A heterozygous factor V Leiden mutation is unlikely to be 
a sufficient cause of this clinical presentation but may con-
tribute to a prothrombotic state by making the hypercoagula-
ble state more difficult to control, particularly in the context 
of the warfarin‐induced inactivation of vitamin K‐dependent 
clotting factors. Warfarin therapy interferes with vitamin K 
epoxide reductase and induces a rapid drop in all vitamin 
K‐dependent clotting proteins, affecting Protein C (half‐
life 5 hours) before Factor VII (half‐life 7 hours) and the 
other clotting factors II, IX, and X (half‐lives 24‐60 hours). 
Antiphospholipid antibodies could promote platelet activa-
tion and exacerbate endothelial injury as part of a possible 
antiphospholipid syndrome (which may further be associated 
with the previous miscarriage). Although the acute symp-
tomatic presentation is unusually severe and the patient did 
not have disseminated intravascular coagulation (Asherson's 
syndrome), the borderline positive result led to the patient 
being treated with plasmapheresis in the hope of stopping the 
prothrombotic state.
However, the patient had a thrombotic event postplasma-
pheresis and did not have the complete features of CAPS. 
Fondaparinux is not recommended in cancer‐associated 
thrombosis and has proved insufficiently effective in this case 
despite therapeutic Anti‐Xa levels.
Having failed two antithrombin‐dependent Xa inhibitors, 
argatroban (which directly inhibits thrombin) was chosen for 
its pharmacokinetic profile, where it reaches steady state over 
1‐3 hours, and has a half‐life of approximately forty minutes. 
This allowed biopsy of her lesion and was the only drug that 
appeared to control her hypercoagulable state.
Dabigatran was chosen as it is pharmacologically simi-
lar to argatroban but can dose orally. Although further study 
is needed, the interaction between crizotinib and dabigatran 
may not be clinically relevant. A number of drug interactions 
listed in the DOAC Summary of Product Characteristics re-
main theoretical.
Venous gangrene is rare, but there is a significant associ-
ation with malignant disease.4 In accord, it seems that there 
is a particular relationship between DVTs and ALK‐positive 
lung neoplasms,5 as seen in this patient. Ten patients have 
been described6 who suffered severe venous limb ischemia/
venous leg gangrene after commencing warfarin treatment 
for a metastatic‐adenocarcinoma‐related DVT, and this pa-
tient may fit this presentation. Of note, these patients expe-
rienced the same thrombocytosis as our patient on starting 
the warfarin/heparin combination therapy. It is likely that the 
heterozygosity for factor V Leiden and IgG anticardiolipin 
antibodies, although each insufficient in isolation to cause 
this degree of hypercoagulability, will have contributed to 
the presentation.
Mechanisms of cancer‐related hypercoagulability appear 
diverse.7,8 Currently, warfarin is the treatment of choice in 
patients with an unprovoked DVT. Commencing warfarin is 
complicated by the induction of a transient prothrombotic 
state through critical reduction in anticoagulants protein C 
and S prior to reduction in the clotting factors II, VII, IX, and 
X. LMWH remains the anticoagulant of choice in cancer‐as-
sociated DVT although edoxaban, an oral Xa inhibitor, was 
shown to be noninferior for cancer‐associated DVT.9 In our 
own practice, we underutilize dabigatran for VTE despite the 
availability of a specific reversal agent which proved to have 
high clinical utility in this case on three occasions including 
for lobectomy. It is possible that conversion to another DOAC 
would be an option after achieving remission from the lung 
cancer.
The similarities between this patient with an adenocarci-
noma of the lung and the series described by Warkentin et al6 
are intriguing. The warfarin failed to control hypercoagula-
bility (despite the supratherapeutic INR) and likely contrib-
uted to venous limb gangrene by compromising the ability of 
the protein C anticoagulant system to downregulate thrombin 
in the microvasculature. The thrombocytosis observed may 
describe a rebound from the reduction in prothrombotic state 
when effective pharmacologic anticoagulation was achieved 
(upon resumption of LMWH), thus reducing platelet activa-
tion and consumption.
We describe for the first time the successful successive 
use of direct thrombin inhibition with argatroban followed 
by oral direct thrombin inhibition with dabigatran. The 
changing therapeutic landscape that has now given us access 
to flexible and rapidly reversible antithrombin independent 
thrombin inhibition has opened a new armamentarium of an-
ticoagulation and bridging which we are yet to fully utilize. 
The absence of detectable dabigatran during the combined 
therapy with dabigatran and crizotinib highlights the ongo-
ing issues with reliably measuring and interpreting dabiga-
tran levels in the small group of patients that requires these. It 
also highlights that the patient's potential benefit from drug 
combination therapy sometimes justifies the risk of causing 
potential interaction provided mitigating interventions are 
put in place to detect potentially significant problems.
The efficacy of direct oral anticoagulants in the treat-
ment of cancer‐associated thrombosis is currently being 
established. Two recent studies have investigated the utility 
of factor Xa inhibitors, namely rivaroxaban, in cancer‐as-
sociated venous thrombosis.10,11 Both appear to conclude 
similar rates of recurrent thromboembolic events when 
comparing rivaroxaban to both heparin and warfarin. It 
may be that the oral anticoagulants will adopt the role of 
the older anticoagulants in cancer‐associated thrombosis in 
the future.
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